Arkolith/Insider Trading/CRNX/Form 4

Pizzuti Dana

Chief Med and Dev OfficerCrinetics Pharmaceuticals, Inc. (CRNX) · full profile →Form 4 · filed Nov 5, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$213K
Net Open-Market Flow
-$213K
Transactions
4
3 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Nov 3, 2025Option exercise(M)5K$16.89$84K71K
Nov 3, 2025Sell(S)5K$42.65$209K66K
Nov 3, 2025Sell(S)100$43.27$4K66K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Nov 3, 2025Option exercise(M)5K—$074K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001628280-25-049671) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML